

Highlights of This Issue 4975

SPECIAL FEATURES

Editorial

- 4977** *AACR Cancer Progress Report 2014: Transforming Lives Through Research*
Jesse Potash and Kenneth C. Anderson


Policy Statement

- 4978** *Reliable and Effective Diagnostics Are Keys to Accelerating Personalized Cancer Medicine and Transforming Cancer Care: A Policy Statement from the American Association for Cancer Research*
Charles L. Sawyers and Laura J. van 't Veer

CCR Translations

- 4982** *The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade*
Antoni Ribas and Paul C. Tumeh
See related article, p. 5064

CCR New Strategies

- 4985** *New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach*
 Amer M. Zeidan and Steven D. Gore

CCR Perspectives in Drug Approval

- 4994** *FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAF^{V600E} Mutation*
Geoffrey Kim, Amy E. McKee, Yang-Min Ning, Maitreyee Hazarika, Marc Theoret, John R. Johnson, Qiang Casey Xu, Shenghui Tang, Rajeshwari Sridhara, Xiaoping Jiang, Kun He, Donna Roscoe, W. David McGuinn, Whitney S. Helms, Anne Marie Russell, Sarah Pope Miksinski, Jeanne Fourie Zirkelbach, Justin Earp, Qi Liu, Amna Ibrahim, Robert Justice, and Richard Pazdur

Molecular Pathways

- 5001** *Molecular Pathways: Deregulation of Histone H3 Lysine 27 Methylation in Cancer—Different Paths, Same Destination*
Teresa Ezponda and Jonathan D. Licht

CANCER THERAPY: CLINICAL

- 5009** *A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer*
Graham S. Taylor, Hui Jia, Kevin Harrington, Lip Wai Lee, James Turner, Kristin Ladell, David A. Price, Manjit Tanday, Jen Matthews, Claudia Roberts, Ceri Edwards, Lesley McGuigan, Andrew Hartley, Steve Wilson, Edwin P. Hui, Anthony T. C. Chan, Alan B. Rickinson, and Neil M. Steven


- 5023** *Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma*
Antonio Omuro, Kathryn Beal, Philip Gutin, Sasan Karimi, Denise D. Correa, Thomas J. Kaley, Lisa M. DeAngelis, Timothy A. Chan, Igor T. Gavrilovic, Craig Nolan, Adilia Hormigo, Andrew B. Lassman, Ingo Mellinghoff, Christian Grommes, Anne S. Reiner, Katherine S. Panageas, Raymond E. Baser, Viviane Tabar, Elena Pentsova, Juan Sanchez, Renata Barradas-Panchal, Jianan Zhang, Geraldine Faivre, Cameron W. Brennan, Lauren E. Abrey, and Jason T. Huse

- 5032** *Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors*
Toshio Shimizu, Patricia M. LoRusso, Kyri P. Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon S. Smith, Drew W. Rasco, Theresa A. Mays, Glenda Chambers, Anna Ma, Jing Wang, Robert Laliberte, Maurizio Voi, and Anthony W. Tolcher

Table of Contents

- 5041** Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303
Ann Marie Egloff, Ju-Whei Lee, Corey J. Langer, Harry Quon, Alec Vaezi, Jennifer R. Grandis, Raja R. Seethala, Lin Wang, Dong M. Shin, Athanassios Argiris, Donghua Yang, Raneeh Mehra, John Andrew Ridge, Urjeet A. Patel, Barbara A. Burtness, and Arlene A. Forastiere

PERSONALIZED MEDICINE AND IMAGING

- 5052** Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
 Yoshihiro Ohue, Koji Kurose, Yu Mizote, Hirofumi Matsumoto, Yumi Nishio, Midori Isobe, Minoru Fukuda, Akiko Uenaka, Mikio Oka, and Eiichi Nakayama

- 5064** Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube, Alison Klein, Julie R. Brahmer, Haiying Xu, Xiaoyu Pan, Jung H. Kim, Lieping Chen, Drew M. Pardoll, Suzanne L. Topalian, and Robert A. Anders
See related commentary, p. 4982

CANCER THERAPY: PRECLINICAL

- 5075** Anti-CCR4 Monoclonal Antibody Mogamulizumab for the Treatment of EBV-Associated T- and NK-Cell Lymphoproliferative Diseases
Tetsuhiro Kanazawa, Yutaka Hiramatsu, Seiko Iwata, Mohammed Siddiquey, Yoshitaka Sato, Michio Suzuki, Yoshinori Ito, Fumi Goshima, Takayuki Murata, and Hiroshi Kimura
- 5085** Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
David Karnak, Carl G. Engelke, Leslie A. Parsels, Tasneem Kausar, Dongping Wei, Jordan R. Robertson, Katherine B. Marsh, Mary A. Davis, Lili Zhao, Jonathan Maybaum, Theodore S. Lawrence, and Meredith A. Morgan

- 5097** Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma
Audrey Lamora, Julie Talbot, Gwenola Bougras, Jérôme Amiaud, Marion Leduc, Julie Chesneau, Julien Taurelle, Verena Stresing, Marie Cécile Le Deley, Marie Françoise Heymann, Dominique Heymann, Françoise Redini, and Franck Verrecchia

BIOLOGY OF HUMAN TUMORS

- 5113** Clinical Implications of Phosphorylated STAT3 Expression in *De Novo* Diffuse Large B-cell Lymphoma
Chi Young Ok, Jiayu Chen, Zijun Y. Xu-Monette, Alexandar Tzankov, Ganiraju C. Manyam, Ling Li, Carlo Visco, Santiago Montes-Moreno, Karen Dybkaer, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W.L. Choi, J. Han van Krieken, Jooryung Huh, Xiaoying Zhao, Maurilio Ponzoni, Andrés J.M. Ferreri, Francesco Bertoni, John P. Farnen, Michael B. Møller, Miguel A. Piris, Jane N. Winter, L. Jeffrey Medeiros, and Ken H. Young

- 5124** Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival
Snehal Dabir, Amy Kluge, Adam Kresak, Michael Yang, Pingfu Fu, Bernd Groner, Gary Wildey, and Afshin Dowlati

- 5133** The Prostate Cancer Susceptibility Variant rs2735839 Near *KLK3* Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients
Yonggang He, Jian Gu, Sara Strom, Christopher J. Logothetis, Jeri Kim, and Xifeng Wu

LETTERS TO THE EDITOR

- 5140** Tumor Stromal Phenotypes Define VEGF Sensitivity—Letter
Gert G. Van den Eynden, Nigel C. Bird, Luc Y. Dirix, Rikke L. Eefsen, Zu-Hua Gao, Gunilla Høyer-Hansen, Martin Illemann, Ali. W. Majeed, Peter Metrakos, Andrew R. Reynolds, Ben Vainer, Pieter-Jan van Dam, Steven J. Van Laere, Peter B. Vermeulen, Fernando Vidal-Vanaclocha, and Pnina Brodt for the Liver Metastasis Research Network



Table of Contents

5141 Tumor Stromal Phenotypes Define VEGF Sensitivity—Response

Neil R. Smith, Dawn Baker, Matthew Farren, Aurelien Pommier, Ruth Swann, Xin Wang, Sunita Mistry, Karen McDaid, Jane Kendrew, Chris Womack, Stephen R. Wedge, and Simon T. Barry

CORRECTION

5142 Correction: A Severe Combined Immunodeficient–hu *In Vivo* Mouse Model of Human Primary Mantle Cell Lymphoma


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows acetylated histone H3 immunohistochemistry staining of skin biopsy at half an hour after the fifth doses of CUDC-101 treatment in the 275-mg/m² cohort. CUDC-101 induces the accumulation of acetylated histone H3. For details, see the article by Shimizu and colleagues on page 5032 of this issue.



Clinical Cancer Research

20 (19)

Clin Cancer Res 2014;20:4975-5143.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/20/19>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/20/19>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.